How well informed are general practitioners and cardiologists about testosterone deficiency and its consequences?
1. Traish, A.M., Adverse health effects of testosterone deficiency (TD) in men. Steroids, 2014. 88C: p. 106-116.
2. Mesbah Oskui, P., et al., Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc, 2013. 2(6): p. e000272.
3. Traish, A.M., Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids, 2014.
4. Corona, G., et al., Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology / European Federation of Endocrine Societies, 2011. 165(5): p. 687-701.
5. Jones, T.H., Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab, 2010. 21(8): p. 496-503.
6. Maggio, M. and S. Basaria, Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res, 2009. 21(4): p. 261-4.
7. Ullah, M.I., et al., Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res, 2011. 43(3): p. 153-64.
8. Wallis, C.J., H. Brotherhood, and P.J. Pommerville, Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice patterns of general practitioners and cardiologists in Victoria, BC. Can Urol Assoc J, 2014. 8(1-2): p. 30-3.
9. Srinivas-Shankar, U., et al., Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab, 2010. 95(2): p. 639-50.
10. English, K.M., et al., Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation, 2000. 102(16): p. 1906-11.
11. Webb, C.M., et al., Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol, 1999. 83(3): p. 437-9, A9.
12. Rosano, G.M., et al., Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 1999. 99(13): p. 1666-70.
13. Webb, C.M., et al., Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation, 1999. 100(16): p. 1690-6.
14. Ong, P.J., et al., Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol, 2000. 85(2): p. 269-72.
15. Kang, S.M., et al., Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol, 2002. 89(7): p. 862-4.
16. Caminiti, G., et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 2009. 54(10): p. 919-27.
17. Malkin, C.J., et al., Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J, 2006. 27(1): p. 57-64.
18. Pugh, P.J., et al., Testosterone treatment for men with chronic heart failure. Heart, 2004. 90(4): p. 446-7.
19. Iellamo, F., et al., Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol, 2010. 56(16): p. 1310-6.
20. Toma, M., et al., Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail, 2012. 5(3): p. 315-21.
21. Mirdamadi, A., et al., Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. Biomed Res Int, 2014. 2014: p. 392432.
22. Stout, M., et al., Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J, 2012. 164(6): p. 893-901.
23. Simon, D., et al., Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab, 1997. 82(2): p. 682-5.
24. Traish, A.M., et al., Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract, 2014. 68(3): p. 314-29.
25. Heufelder, A.E., et al., Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl, 2009. 30(6): p. 726-33.
26. Zitzmann, M. and E. Nieschlag, Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab, 2007. 92(10): p. 3844-53.
27. Haider, A., et al., Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. . Obes Res Clin Pract 2013.
28. Haider, A., et al., Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. International Journal of Endocrinology, 2014: p. Article ID 683515.
29. Mitkov, M.D., I.Y. Aleksandrova, and M.M. Orbetzova, Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv), 2013. 55(1): p. 55-63.
30. Yassin, D.J., et al., Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med, 2014. 11(6): p. 1567-76.
31. Caldas, A.D., et al., Relationship between insulin and hypogonadism in men with metabolic syndrome. Arq Bras Endocrinol Metabol, 2009. 53(8): p. 1005-11.
32. Laaksonen, D.E., et al., The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab, 2005. 90(2): p. 712-9.
33. Singh, S.K., R. Goyal, and D.D. Pratyush, Is hypoandrogenemia a component of metabolic syndrome in males? Exp Clin Endocrinol Diabetes, 2011. 119(1): p. 30-5.
34. Pellitero, S., et al., Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg, 2012. 22(12): p. 1835-42.
35. Biswas, M., et al., Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf), 2012. 76(5): p. 665-73.
36. Holm, A.C., et al., Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Aging Male, 2011. 14(4): p. 249-56.
37. Bhasin, S., et al., Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab, 2011. 96(8): p. 2430-9.
38. Bhasin, S., et al., Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2010. 95(6): p. 2536-59.
39. Wang, C., et al., Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl, 2009. 30(1): p. 1-9.